Risk Factors Update Summary

• Additional material weaknesses or restatements in financial results may lead to litigation risks.
• The company may rely on third parties for safety and effectiveness data, increasing risk.
• Failure to meet continued listing requirements could reduce liquidity and impact stock price.
• Identified material weakness in internal control over financial reporting may result in disputes.
• Candidates Clinical was added to the risk factors, highlighting the importance of clinical trials.
• Potential undesirable side effects could require managing additional relationships, affecting operations.
• Enhanced cybersecurity measures to protect against unauthorized access and data loss implemented.
• Inconclusive results in clinical trials may impact regulatory approval. This change emphasizes uncertainty.
• Competition from generic products may impact revenue and profitability, affecting market position.
• Marketing approval requires costly post-marketing trials, impacting financials.